Latest Commercial Sales News

Rhythm Biosciences has obtained a $1 million non-dilutive loan backed by its FY2025 R&D Tax Incentive rebate, aiming to accelerate the commercial rollout of its ColoSTAT® test and expand its geneType™ platform.

Argosy Minerals has executed a spot sales contract for 60 tonnes of high-purity lithium carbonate from its Rincon project, marking a significant step in its lithium market engagement.

Paradigm Biopharmaceuticals has acquired Proteobioactives, securing global rights to an oral combination therapy targeting early-stage osteoarthritis in humans and animals, complementing its injectable PPS phase 3 program.

Green Critical Minerals has raised A$7 million through an institutional placement to accelerate the commercial rollout of its Very High Density graphite technology, aiming for first revenue in early 2026.

TruScreen Group Limited forecasts a robust 64% increase in FY26 sales, driven by strategic market expansions and new distribution agreements. The company’s AI-enabled cervical cancer screening technology is gaining traction across emerging markets.

Syrah Resources has clarified its offtake agreement with Tesla, extending the final qualification deadline for its Vidalia anode active material facility to February 2027. Both companies continue advancing towards commercial sales despite the extended timeline.

Orthocell has rapidly expanded its US distributor network for Remplir™, surpassing its target ahead of schedule and positioning itself for imminent sales in the $1.6 billion nerve repair market.

AVITA Medical reported a strong first quarter with revenues up 67% to $18.5 million, driven by expanded commercial sales and new product introductions. Despite a narrower net loss, the company faces ongoing challenges from revenue covenants and macroeconomic pressures.

Aguia Resources reports steady underground mining at 15 tonnes per day at its Santa Barbara Gold Project, with plans to boost processing capacity to 50 tonnes per day by July 2025 and imminent gold sales.

Zimi Limited has paused its planned capital raising amid ongoing talks, while revealing strong operational momentum including $1.42 million in open orders and expanded market partnerships.

Dimerix has received a US$30 million upfront payment from Amicus Therapeutics for exclusive US rights to DMX-200, a promising kidney disease therapy. The deal positions Dimerix for up to US$560 million in further milestones plus royalties, underpinning its global licensing strategy.

Pure Hydrogen Corporation has marked significant progress in its clean energy transition, delivering Australia's first hydrogen fuel cell garbage truck and securing multi-million dollar contracts with industry leaders TOLL Transport and Heidelberg Materials.